Unknown

Dataset Information

0

Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus.


ABSTRACT: Adjunctive therapies to insulin for treatment of type 1 diabetes mellitus (T1D) have gained popularity in efforts to achieve glycemic targets, and sodium-glucose transporter (SGLT) inhibitors are an appealing option due to associated weight loss, low risk of hypoglycemia, and improved cardiorenal outcomes seen in persons with type 2 diabetes mellitus. The increased risk of diabetic ketoacidosis (DKA), including euglycemic DKA, has led many to be wary of their use in T1D, especially given limited pediatric data and data regarding cardiorenal protection in this population. The phase 3 trials of these agents in T1D have yielded lower HbA1c, decreased total daily insulin dose, and small but significant weight loss with no increase in hypoglycemia. These trials also reported increased risks of genital mycotic infection and DKA. SGLT inhibitors have been approved as adjunctive therapy to insulin in adults with T1D in Europe and Japan, but the United States Food and Drug Administration has rejected similar applications. Although approaches to mitigate the risk of DKA have been developed, no randomized trials using such tools have been conducted. More research is needed to minimize the risk of DKA and to better evaluate the cardiorenal impact of these agents in persons with T1D.

SUBMITTER: Vitale RJ 

PROVIDER: S-EPMC8849139 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5485046 | biostudies-literature
| S-EPMC6848551 | biostudies-literature
| S-EPMC8272340 | biostudies-literature
| S-EPMC5518299 | biostudies-literature
| S-EPMC3889318 | biostudies-literature
| S-EPMC4758393 | biostudies-literature
| S-EPMC6028052 | biostudies-literature
| S-EPMC6945755 | biostudies-literature
| S-EPMC7033896 | biostudies-literature
| S-EPMC6852284 | biostudies-literature